PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells
William J. Israelsen1, Talya L. Dayton1, Shawn M. Davidson1, Brian P. Fiske1, Aaron M. Hosios1, Gary Bellinger1, Jie Li2, Yimin Yu1, Mika Sasaki3, James W. Horner4, Laura N. Burga3, Jianxin Xie5, Michael J. Jurczak6, Ronald A. DePinho4, Clary B. Clish7, Tyler Jacks1, Richard G. Kibbey6,8, Gerburg M. Wulf3, Dolores Di Vizio9,10,11, Gordon B. Mills2
1Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, MA 02139, USA
2Department of Systems Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
3Department of Medicine, Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA
4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115 USA
5Cell Signaling Technology, Danvers, MA 01923, USA
6Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06510, USA
7Metabolite Profiling Platform, Broad Institute, Cambridge, MA 02142, USA
8Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT 06510, USA
9Division of Cancer Biology and Therapeutics, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
10The Urological Diseases Research Center, Boston Children's Hospital, Boston, MA 02115, USA
11Department of Surgery, Harvard Medical School, Boston, MA 02115, USA